The potential market for Endonovo's technology is truly staggering.

In the United States, approximately 1.1 million cases of myocardial infarction (MI) occur annually, according to the American Heart Associations' Heart Disease and Stroke Statistics -- 2016 Update. MI is a condition where myocardial ischemia, a diminished blood supply to the heart, exceeds a critical threshold and overwhelms myocardial cellular repair mechanisms designed to maintain normal operating function and homeostasis. Ischemia at this critical threshold level for an extended period results in irreversible myocardial cell damage or death, and can result in heart failure.

The market for chronic kidney disease (CKD) drugs is estimated to reach $15.8 billion by 2024,

The epidemic of diabetes and metabolic syndrome has increased the number of lower-extremity problems presenting for treatment. It is estimated that 50% of diabetic patients have evidence of chronic limb ischemia. Globally, diabetes accounts for 1 amputation every 30 seconds and 80,000 amputations annually in the United States.

The market for a NASH treatment is estimated to reach $35 to $40 billion by 2025,

The global in-vitro toxicology testing market was valued at $20.2 billion in 2014 with forecasts projecting it reaching a value of $44.7 billion by 2020, growing at an estimated CAGR of 10.5% from 2015 to 2022, according to Grand View Research. The increase in demand for in-vitro toxicology testing is attributable to novel and promising technologies in analytical laboratories, such as organ-on-a-chip technologies and bioinformatics.